ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number 2019252920, entitled, “Simultaneous Multi-Site Vagus Nerve Neuromodulation For Improved Glycemic Control System And Methods,” will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.

Read more at globenewswire.com